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Abstract
Background: The appearance of Ab42 peptide deposits is admitted to be a key event in the pathogenesis of
Alzheimer’s disease, although amyloid deposits also occur in aged non-demented subjects. Ab42 is a degradation
product of the amyloid protein precursor (APP). It can be catabolized by several enzymes, reabsorbed by capillaries
or cleared into cerebrospinal fluid (CSF). The possible involvement of a decrease in CSF turnover in A4b2 deposit
formation is up to now poorly known. We therefore investigated a possible relationship between a reduced CSF
turnover and the CSF levels of the A4b2 peptide.
To this aim, CSF of 31 patients with decreased CSF turnover were studied. These patients presented chronic
hydrocephalus communicating or obstructive, which required surgery (ventriculostomy or ventriculo-peritoneal
shunt). Nine subjects had idiopathic normal pressure hydrocephalus (iNPH), and the other 22 chronic
hydrocephalus from other origins (oCH).
The Ab42 peptide concentration was measured by an ELISA test in 31 ventricular CSF samples and in 5 lumbar CSF
samples from patients with communicating hydrocephalus.
Results: The 5 patients with lumbar CSF analysis had similar levels of lumbar and ventricular Ab42. A significant
reduction in Ab42 ventricular levels was observed in 24 / 31 patients with hydrocephalus. The values were lower
than 300 pg/ml in 5 out of 9 subjects with iNPH, and in 15 out of 22 subjects with oCH.
Conclusion: The decrease of CSF Ab42 seems to occur independently of the surgical hydrocephalus aetiology. This
suggests that a CSF reduced turnover may play an important role in the decrease of CSF Ab42 concentration.
Background
Alzheimer’s disease (AD) is characterized by the pre-
s e n c eo fd i f f u s ea n ds e n i l ed e n s e - c o r ep l a q u e s .S e n i l e
plaques may also be seen in non-demented elderly
patients. According to the « amyloid theory », the
appearance of Ab42 deposits is considered as the crucial
event in the evolution of AD [1].
Ab42 can be reabsorbed by capillaries via specific
receptors, the most charaterized being LRP-1 [2],
degraded by several enzymatic pathways or cleared into
cerebrospinal fluid (CSF) [3]. In AD patients, Ab42 pro-
duction is similar to that of cognitively normal controls,
but its clearance is impaired [4]. The CSF turnover is
defined by the volume of CSF produced in 24 hours
divided by the volume of the CSF space. It can be
estimated to 4 volumes per day for healthy young adults
[5]. The consequences of decreased CSF turnover on
the clearance of Ab42 were still unknown.
In vitro, Ab42 monomers, incubated into CSF, build
spontaneously oligomers and then fibrils; these phenom-
ena are time-dependant [6,7]. Experimentally, it has
been shown that brain amyloid deposits accumulate in
rats with kaolin-induced hydrocephalus [2]. In this
model, immunochemistry shows an accumulation of
Ab42 without significant increase in APP expression.
This is associated to an increase in p-tau and a loss of
dendritic staining. Altered CSF turnover seems to affect
Ab42 clearance and to favour amyloid cerebral deposit
formation [8].
Several human types of chronic hydrocephalus with
altered CSF turnover are known, such as idiopathic Nor-
mal Pressure Hydrocephalus (iNPH), and those follow-
ing meningeal haemorraghe or related to surgery for
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rare disease (about 1 case for 200000 people), described
in 1965, and characterized by a clinical triad of mental
alteration, gait disturbance and sphincter dysfunction
[9]. In this affection, ventricular dilatation has also been
described, with a normal pressure of lumbar CSF, a per-
turbation of CSF resorption, and a correlative reduction
in CSF turnover to less than 1.5 volume per day instead
of 4 volumes as seen in young controls [5]. In AD, CSF
turnover is also reduced and can be estimated to less
than 1.5 volume per day [5,10].
In order to investigate a possible involvement of a
decrease in CSF turn-over on Ab42 clearance, we stu-
died the ventricular levels of this peptide in patients suf-
fering from chronic hydrocephalus, which required
surgery (ventriculostomy or ventriculo-peritoneal shunt).
We compared lumbar and ventricular CSF levels in
some patients with communicating hydrocephalus, we
found ventricular levels are decreased in iNPH and simi-
lar to those measured in patients suffering from chronic
hydrocephalus, communicating or obstructive.
Methods
The prospective study was performed on a panel of 31
consecutive patients (men: 17, women: 14), aged from
28 to 86 years (mean age 64.9 ± 15.5 years; median 68
years). All of them were affected with chronic hydroce-
phalus from various aetiologies, which required either a
ventriculostomy or a ventriculo-peritoneal shunt. In
Phase Contrast MRI, all the patients had ventricular
dilatation and periventricular edema due to transepen-
dymal resorption of CSF; the patients with communicat-
ing hydrocephalus were also characterized by
hyperdynamic aqueductal CSF flow [11].
The experimental protocol was the following: during
the surgery, 3-4 cm
3 of CSF were aspired, as usual, in
order to check the position or the functionality of the
shunt. After sampling for cyto-bacteriological analysis,
residual CSF was immediately aliquoted in polypropy-
lene tubes placed on ice, and transported to the Bio-
chemistry Laboratory, wherei tw a sc e n t r i f u g e da t4 0 0 0
× g for 10 min., then stored at - 80°C. This study was
achieved according to the French bioethic rules for clini-
cal studies on tailing samples. All the patients gave first
their agreement for this protocol.
The respective diagnoses for these patients were: 9
iNPH, and 22 chronic hydrocephalus from other origins
(oCH): 3 related to a meningitis or a meningeal haemor-
rhage, 4 due to stenosis of the Sylvius aqueduct, 10 from
benign or malignant tumor origin, 2 following a menin-
gioma surgery, 2 due to a Arnold-Chiari syndrome or a
neonatal hydrocephaly and one secondary to the rupture
of a dermoid cyst. Five out of these patients (3 with
iNPH and 2 with hydrocephalus post subarachnoidal
haemorraghe, all older than 65 years) also benefited of a
prior subtractive lumbar tap.
The concentrations of Ab42 were measured using a
commercial ELISA test (Innotest b-amyloid [1-42] from
Innogenetics, Ghent, Belgium). With this method, the
intra-assay variability coefficient is less than 6%. The
range for the titration zone is 125-2000 pg/ml. CSF
lumbar Ab42 levels higher than 500 pg/ml are consid-
ered as normal [12].
Statistics
Ventricular Ab42 values in the two groups (iNPH, oCH)
were compared using the Student’ t test corrected for
unequal variance. Correlations between values of Ab42
measured in lumbar and ventricular CSF, were analyzed
using the Pearson’s test. P < 0.05 were considered as
significant.
Results
There was no correlation between Ab42 levels and age.
In the 5 patients with lumbar CSF analysis, lumbar and
ventricular Ab42 levels (respectively 415.6± 180.8 pg/ml
and 378.4± 189 pg/ml; p>0.05) were found similar and
highly correlated (r = 0.99; Figure 1). Based on this fact,
Ab42 ventricular values lower than 500 pg/ml were con-
sidered as reduced. This is the case for 24/31 patients
(77%), with values under 300 pg/ml in 20 patients (64%)
including 5 out of 9 iNPH (55%) and 15 out of 22 oCH
(68%; figure 2).
It can also be observed in Figure 2 that no significant
difference was found between the iNPH and oCH
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Figure 1 Correlation between lumbar and ventricular CSF
levels of Ab42 (values are expressed in pg/ml; R
2 = 0.989, P <
0.0001).
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Page 2 of 5groups for ventricular Ab42 levels (respectively 297.1 ±
343.3 pg/ml and 206.7 ± 194.8 pg/ml, p > 0.2; median
values 286 and 211 pg/ml).
Discussion
This work shows that ventricular and lumbar levels of
Ab42 are closely related in communicating hydrocepha-
lus; they are low in iNPH, and comparable to those of
other surgical hydrocephalus.
The main limit of this study is that, for ethic reasons,
we cannot compare the obtained data to the concentra-
tions existing in “normal” subjects. CSF is a transport
medium for numerous molecules (nutriments, growing
factors, terminal products of brain cell metabolism). The
ventricular and lumbar protein concentrations are often
different, depending upon their origin. Indeed, brain
proteins are considered to generally exhibit a higher
level in intraventricular CSF, whereas blood proteins are
more concentrated in lumbar CSF [13,14]. However,
there are many exceptions; for example, concentrations
of transthyretin, a protein synthesized by choroid plexus,
are nearly the same in ventricular and lumbar CSF [15].
There are no available reference values well estab-
lished for Ab42 ventricular levels in healthy individuals.
Therefore, we measured Ab42 levels in lumbar and ven-
tricular CSF of 5 patients with chronic communicating
hydrocephalus and we found that ventricular and lum-
bar Ab42 values are not significantly different. Despite
the small sample size, this fact suggests the ventricular
CSF Ab42 concentrations measured in this study seem
to be relevant for a comparison with those existing in
lumbar CSF of control subjects.
In iNPH, several studies [16-19] demonstrated that the
lumbar Ab42 levels are lowered. Our results are in good
agreement with these previous data: more than 75% of the
studied patients, whatever the aetiology of the hydroce-
phalus, exhibit reduced Ab42 levels in their ventricular
CSF. The fact that the ventricular Ab42 levels were similar
iNPH and oCH suggests some similarities in the patho-
physiological process despite the existing differences in
CSF dynamics and aetiologies. The same findings were
reported for other proteins (neurofilament light protein,
tau, sulfatide, vasoactive intestinal peptide and neuropep-
tide Y) in case of iNPH and aqueductal stenosis [20]. Sev-
eral hypotheses could explain this decrease of Ab42 levels.
Several hypothesis might be put forward to explain the
decrease in Ab42 levels. First, oligomer formation,
favoured by the altered CSF turnover in NPH, could
partially mask the antigenic sites of the peptide, espe-
cially the C-terminal part, which is hidden inside the
hydrophobic core of the aggregate. This therefore could
lead to an underestimation of the Ab42 levels when
using an ELISA technique [21]. Second, Ab42 glycation
could contribute to an underestimation of the protein
concentration by ELISA. Indeed, the CSF glucose con-
centration is relatively high (about 0.5g/l), and CSF sta-
sis promotes Amadori products formation [22], which
could also mask some antigenic sites of the peptide.
Third, a reduced production of Ab42 could be sus-
pected, as described in Creutzfeldt-Jacob’sd i s e a s e .I n
this affection, there are no Ab42 deposits and CSF Ab42
levels are significantly reduced [23], this probably due to
the inhibition of b-secretase cleavage by PrP(C) [24].
However, an intra-cerebral sequestration of amyloid
protein most likely occurs. Strozyk et al,i n v e s t i g a t i n g
the relationship between amyloid neuropathology and
post-mortem CSF Ab42 levels in an autopsy sample of
155 patients with dementia found that a high number of
plaques is associated with reduced levels of ventricular
Ab42 [25].
The « B compound of Pittsburgh » (PIB), a thioflavine
derivative, which is a ligand of Ab42, is able, after i.v.
injection, to cross the blood brain barrier and bind to
Ab peptides. Molecular neuroimaging allows to detect
amyloid pathology in vivo using PET scanning with PIB
[26]. Several authors [27,28] using the PIB PET scan-
ning, demonstrated, in patients with Alzheimer disease,
that Ab42 lumbar levels are lowered and inversely cor-
related to the Ab load of brain. With the same techni-
que, Leinonen et al [29] demonstrated the occurrence of
amyloid deposits in 5/10 patients with iNPH, and cere-
bral biopsies performed during shunt surgery confirmed
the existence of amyloid deposits in these patients. In a
large follow-up study of NPH, idiopathic or secondary,
Leinonen et al [30] also showed, on small cortical brain
biopsies obtained during surgical treatment, that 186/
433 (43%) patients displayed Ab42 deposits. These
lesions of AD are more frequent among older subjects
Figure 2 Comparison of ventricular Ab42 levels between iNPH
and other hydrocephalus. The space between 2 horizontal lines is
the interquartile range. The boxes represent the 25
th,5 0
th and 75
th
percentiles (values are expressed in pg/ml).
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reduced transport via LRP-I [2,32] and lower activities
of some enzymes involved in the catabolism of the
Ab42 peptide [33]; this suggests an increasing role of
the CSF turnover in Ab42 clearance during aging.
It is interesting to note, based on data derived from the
ADNI database, an inverse correlation between ventricu-
lar size and CSF Ab42 levels is observed in controls, MCI
and AD, which also supports the hypothesis that the CSF
turnover could play an important role in the regulation
of the CSF Ab42 peptide concentration [34].
Conclusion
Our study shows that ventricular and lumbar levels of
Ab42 are not significantly different in surgical commu-
nicating hydrocephalus. Patients with iNPH exhibit a
frequent decrease in ventricular CSF Ab42 peptide
levels, which is in good agreement with decreased lum-
bar levels previously described. This is consistent with
an intra-cerebral sequestration of the peptide resulting
from the reduced CSF turnover. Similarly, patients with
surgical chronic hydrocephalus of other origins show an
impairment of CSF turnover and also exhibit a decrease
in Ab42 ventricular levels. Thus, the decline in CSF
Ab42 concentration is not specific of iNPH and seems
independent of the surgical hydrocephalus aetiology.
This study suggests that the reduced CSF turnover is a
key event in the decrease of Ab42.
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